Items Tagged ‘radium-223’

November 6th, 2014

Xofigo Extends Survival in Hormone-Refractory Prostate Cancer


For patients with advanced hormone-refractory prostate cancer, the agent Xofigo® (radium-223) appears similarly effective in patients who have and have not received Taxotere® (docetaxel), a chemotherapy drug that can be used in the treatment of advanced prostate cancer. These findings were recently published in The Lancet Oncology. Prostate cancer is a hormonally sensitive disease that […]

View full entry

Tags: Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, radium-223, Refactory/Recurrent Prostate Cancer, taxotere, xofigo